|  |
| --- |
| **Marie ROBERT** |



Mobile: +33(0)6 17 49 52 54

E-mail: marie.robert07@outlook.com/marie.robert2@aphp.fr

3 rue Bargue, 75015 Paris

|  |
| --- |
| **SCOLARITE** |
| **2020 - 2022****2017 - 2020****2016 - 2017** | * **Diplôme d’études spécialisées en médecine interne et immunologie clinique – Assistance Publique des Hôpitaux de Paris**
* **DIU des maladies auto-inflammatoires et amyloses inflammatoires**
* **DIU Études approfondies des polyarthrites et maladies systémiques –** Club Rhumatismes et inflammation
* **DIU Manifestations dermatologiques des maladies systémiques**
* **Deuxième cycle des études de médecine – Faculté de Médecine Lyon Est**
* **Master 2 de Sciences – Biologie Moléculaire de la Cellule – Université Pierre et Marie Curie Paris IV – Parcours Immunologie – Immunopathologie**
	+ **Master in Life Sciences IMaLiS  – Ecole Normale Supérieure de Paris – Ulm** Computational Systems biology and genomics
	+ **Cours d’immunologie approfondie**  **- Institut Pasteur**
* **Premier Cycle des études de médecine – Faculté de Médecine Lyon Est**
* Master 1: Immunologie et Immunopathologie; Biologie moléculaire de la cellule.
* **Lauréate de l’Ecole de l’INSERM Liliane Bettencourt** – Promotion 2015
 |
| **2012 - 2016** |
|  |
|  |
| **EXPERIENCES PROFESSIONNELLES** |
| **2020 - 2022****2015 - 2020****2016 - 2018** | * **Interne en médecine interne et immunologie clinique – Assistance Publique des Hôpitaux de Paris**
* **Externe des Hospices Civils de Lyon**
* **Stage de Recherche - Immunogénomique et inflammation** – Equipe du Pr Miossec – Hôpital Edouard Herriot (Lyon)
* **Stage de Recherche – Département de recherche translationnelle et innovation –** Equipe du Dr Saintigny/Pr Puisieux - Centre Leon Bérard/Centre de Recherche en Cancérologie de Lyon (Lyon)
 |
| **PUBLICATIONS – *h-*index 5 ; 251 citations ; ORCID : 0000-0002-1374-6210*****Articles :**** Robert, M., & Hot, A. Atrophic papulosis. *Dermatology* (Accepted)
* Foy, JP., […] Robert, M., […], Saintigny, P. Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors. *Data in Brief* (In Press)
* Foy, JP., […] Robert, M., […], Saintigny, P. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. *Eur J Cancer* (In Press).
* Ortiz-Cuaran, S., […], Robert, M., […] Saintigny, P. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. *Eur J Cancer* (In Press).
* Robert, M., Miossec, P., Hot, A. The Th17 Pathway in Vascular Inflammation: Culprit or Consort? *Front Immunol* 2022;13:888763.
* Robert, M., Farese, H., Miossec, P. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features. *Front Immunol* 2022;13:820046.
* Peter, E\*., Robert, M\*., Guinet, V., Krolak-Salmon, P., Desestret, V., Jacquin-Courtois, S., Cohen, F., Seve, P., Garnier-Crussard, A*.* Importance of cognitive disorders in internal medicine: Pathophysiology, diagnosis, management. The example of systemic lupus erythematosus. *Rev Med Interne* 2022;43, 39-47.
* Robert, M., Miossec, P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. *Cell Mol Immunol* 2021;**18**:1644-51.
* Peter, E., Robert, M., Guinet, V., Krolak-Salmon, P., Desestret, V., Jacquin-Courtois, S.,Cohen, F., Seve, P., Garnier-Crussard, A*.* Towards a better recognition of cognitive disorders in internal medicine?. *Rev Med Interne* 2021;42, 299-301.
* Robert, M., Hot, A., Mifsud, F., Ndongo-Thiam, N. & Miossec, P. Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up. *Front Med (Lausanne)* **7**, 556086 (2020).
* Robert, M., Hot, A., Mifsud, F., Ndongo-Thiam, N. & Miossec, P. Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis. *Front Immunol* **11**, 1998 (2020).
* Siouda, M., Dujardin, AD., Barbollat-Boutrand, L., Mendoza-Parra, MA., Gibert, B., Ouzounova, M., Bouaoud, J., Tonon, L., Robert, M., Foy, JP., Lavergne, V., Manie, SN., Viari, A., Puisieux, A., Ichi, G., Gronemeyer, H., Saintigny, P., Mulligan, P. CDYL2 Epigenetically Regulates MIR124 to Control NF-kappaB/STAT3-Dependent Breast Cancer Cell Plasticity. *iScience* **23**, 101141 (2020).
* Robert, M. & Miossec, P. Interleukin-17 and lupus: enough to be a target? For which patients? *Lupus* **29**, 6-14 (2020).
* Robert, M. & Miossec, P. IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. *Front Med (Lausanne)* **5**, 364 (2018).
* Robert, M. & Miossec, P. Effects of Interleukin 17 on the cardiovascular system. *Autoimmun Rev* **16**, 984-991 (2017).

***Chapitres :**** Robert M. & Mouthon, L. La Sclérodermie systémique – Le Traité de Médecine - Elsevier Masson.
* Robert M. & Miossec, P. Cellular side of acquired immunity (T cells) – Oxford Textbook of Rheumatology.

***Livre :*** Bouvier A, Duchamp B, Robert M. *L’immunologie facile aux ECNi.* Elsevier Masson. |